UK Medical Cannabis Market Reaches 100 Million Annual Revenue

The UK medical cannabis market has reached a landmark financial milestone, with annual revenues surpassing one hundred million pounds for the first time. Industry analysts and patient advocacy groups alike are pointing to the figure as evidence of a sector that has matured significantly since medical cannabis was rescheduled in November 2018.

Growth Drivers

Several factors have contributed to the market's rapid expansion. Rising patient awareness, a broadening clinical evidence base, increased prescriber confidence, and an expanding range of approved products have collectively driven demand upward year on year.

• Active patient numbers now exceeding 150,000 across licensed clinics
• Average monthly prescription values rising as more complex conditions are treated
• New product categories including high-CBD oils, balanced THC:CBD flowers, and oral capsules entering the market
• Private clinic networks expanding nationally to meet patient demand

Market Composition

The majority of UK medical cannabis revenue is generated through private clinical channels, with NHS prescribing remaining limited to specific conditions. Imported products from licensed international producers in the Netherlands, Canada, Portugal, and Germany continue to account for the majority of dispensed products, though domestic cultivation under Home Office licence is contributing an increasing share.

Patients can compare currently available products through our full strain directory and read more about the prescription process in our patient guide. For clinic options, visit our clinic finder. Industry bodies have called on the government to use this milestone as an opportunity to review the regulatory framework.